HCW Biologics Q4 2023 Earnings Report $0.35 -0.02 (-5.41%) As of 04:00 PM Eastern Earnings History HCW Biologics EPS ResultsActual EPS-$0.30Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AHCW Biologics Revenue ResultsActual Revenue$1.32 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHCW Biologics Announcement DetailsQuarterQ4 2023Date4/1/2024TimeN/AConference Call ResourcesHCWB Earnings History HCW Biologics Earnings HeadlinesHCW Biologics CEO to address opportunities, challenges in biomanufacturingJanuary 15, 2025 | markets.businessinsider.comHCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025January 15, 2025 | globenewswire.comMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.January 21, 2025 | Brownstone Research (Ad)HCW Biologics receives notice on failing to regain compliance from NasdaqDecember 23, 2024 | markets.businessinsider.comBroward pharma business could be delisted from stock exchangeDecember 23, 2024 | bizjournals.comHCW Announces Written Notice from NASDAQDecember 23, 2024 | baystreet.caSee More HCW Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email. Email Address About HCW BiologicsHCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.View HCW Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025)ICICI Bank (1/22/2025)Johnson & Johnson (1/22/2025)Kinder Morgan (1/22/2025)Procter & Gamble (1/22/2025)Progressive (1/22/2025)Travelers Companies (1/22/2025)CSX (1/23/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
